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ABSTRACT 
 
 It has been postulated that endothelial cell injury is the initiating event in the 
pathogenesis of systemic sclerosis, causing attraction, attachment, migration and 
infiltration of activated T cells and subsequent production of cytokines and growth 
factors. As a result of the action of these cytokines and growth factors, chemoattraction of 
fibroblasts into the vessel wall and trans-differentiation of resident fibroblasts and smooth 
muscle cells into myofibroblasts occurs leading to fibrosis and exaggerated collagen 
deposition in the vessel wall.  The vascular fibroproliferative lesion in systemic sclerosis 
is frequently accompanied by severe vasomotor instability manifested clinically by the 
occurrence of Raynaud’s phenomenon, as well as, by an exaggerated vasoconstrictor 
response in the visceral microvasculature, particularly, in the kidneys, the lungs, and the 
myocardium.  The fibroproliferative vascular occlusion coupled with the vasospastic 
response causes hypoxia and additional endothelial injury propagating further the 
vascular fibrotic lesion. To date, the therapeutic options for the vasculopathy of systemic 
sclerosis have been limited to drugs that cause vasodilation and inhibit platelet 
aggregation and only a few agents have shown vascular remodeling effects.  Therapeutic 
agents which could potentially modify the course of this vasculopathy may have a disease 
modifying effect, particularly, if instituted in the early stages of the disease. 
Extensive recent studies have shown that statins display numerous effects 
independent of their well established lipid-lowering effect that may be of potential benefit 
in preventing vascular injury and ischemic vascular events.  These effects may both 
prevent and improve vessel wall abnormalities, as well as, cause a local increase in the 
production and secretion of vasodilating molecules.  Here, we review the current 
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literature to provide support of a testable hypothesis that postulates that statins may have 
a modifying effect on the vasculopathy of systemic sclerosis.  
 
INTRODUCTION 
 Vascular dysfunction and structural vessel wall abnormalities appear to be among 
the earliest alterations in systemic sclerosis.  Indeed, it has been suggested that 
endothelial cell and vascular injury may be the crucial initiating event in the pathogenesis 
of this disorder (1, 2).  Endothelial dysfunction is one of three fundamental abnormalities 
characteristic of systemic sclerosis; the others being tissue fibrosis caused largely by 
increased collagen gene expression in dermal and visceral fibroblasts, and alterations in 
humoral and cell mediated immunity (3).  The profound functional endothelial cell 
alterations in systemic sclerosis result in the progressive obliteration of the lumen of 
small arterioles and capillaries by newly formed fibrotic tissue causing a severe 
vasculopathy which most commonly involves the microvascular system.  The most 
common clinical manifestation of this unique vasculopathy is the occurrence of 
Raynaud’s phenomenon with narrowing and eventual occlusion of digital vessels.  
However, visceral organs such as the kidneys, lungs, heart and skeletal muscle are also 
frequently involved (4).  
 Smooth muscle cells in the intimal layer of the vessel wall become activated 
likely owing to their transdifferentiation into myofibroblasts, migratory cells which 
characteristically display a marked increase in collagen production, causing an 
exaggerated deposition of collagen and other extracellular matrix macromolecules in the 
tissue.  This fibroproliferative lesion coupled with the exaggerated vasoconstrictive 
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vascular response typical of systemic sclerosis causes chronic hypoxia that leads to 
further endothelial injury and fibrosis. The severe vasomotor instability in these vessels is 
caused by 2c adrenergic hyperactivity, the local overproduction of vasoconstrictive 
substances such as endothelin, and the reduced production of local vasodilating agents 
such as NO. The narrowing of the vessel lumen and the endothelial dysfunction further 
propagate tissue ischemia by inducing platelet aggregation and local thrombosis (3, 4). 
 Therapy for the vasculopathy of systemic sclerosis has included vasodilator 
agents such as calcium channel blockers, prostaglandins, phosphodiesterase inhibitors, 
endothelin receptor inhibitors, and agents causing increased NO production such as 
nitroglycerin (5), as well as, antiplatelet agents to prevent thrombotic vessel occlusion 
and platelet aggregation.  Some of these agents such as angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, prostaglandins and endothelin receptor 
inhibitors have also been shown to cause some vascular remodeling and improvement of 
the intimal fibrotic lesion.  In this regard, it is of substantial interest that recent studies 
have suggested that the statins may also interfere with the pathological changes in the 
vessel wall (6, 7).   It is well established that suppression of elevated total and low 
density lipoprotein cholesterol levels by statins promotes primary and secondary 
prevention of ischemic, atherosclerotic related events in patients with 
hypercholesterolemia (8-13). This effect was initially believed to be solely related to the 
cholesterol lowering effects of the statins, however, there is increasing evidence that 
these agents may exert profound endothelial and vascular protective effects beyond their 
lipid lowering action (14-16).  Indeed, experimental studies have shown that statins 
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protect normocholesterolemic animals from the development of myocardial infarction 
(17).  
These later clinical and experimental observations have led to a wealth of research 
studies examining the pleiotropic effects of statins including modification of vascular 
pathology and have allowed the suggestion that these agents may have beneficial effects 
in other diseases accompanied by vasculopathy.  In order to understand these pleiotropic 
effects, it is necessary to understand the metabolic pathways upon which these agents 
exert their cholesterol lowering effect.  Statins inhibit the 3-hydroxy-3 methylglutanyl 
coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the formation of 
mevalonate from HMG-CoA, the earliest step in the production of cholesterol (Figure1). 
As can be seen in the diagram, mevalonate is also the precursor of isoprenoid groups 
which are required to modify post-translationally the Rho and Ras-superfamilies of 
proteins by attaching a hydrophilic prenyl group, either farnesyl or geranylgeranyl.  The 
Rho and Ras proteins are small membrane-bound GTPases, which are active in the GTP-
bound state and inactive in the GDP-bound state.  In their active state these proteins 
regulate important cellular functions including cell survival, proliferation and 
differentiation, as well as, cytoskeletal organization, by relaying extracellular ligand-
stimulated signals to cytoplasmic signaling cascades. It is the inhibition of prenylation of 
the Rho and Ras-related proteins by statins that is postulated to be responsible for some 
of the pleiotropic effects of this class of agents (18-21). 
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Making a Case for Statin Use in Systemic Sclerosis Vasculopathy 
 Statins as immune modulating agents.    As described above, endothelial injury 
and the development of a vasculopathy have been postulated to be the initial pathogenic 
events in the development of systemic sclerosis.  Endothelial injury which in some cases 
may be augmented by circulating antiendothelial antibodies (22), leads to attraction, 
attachment, migration and local infiltration of activated T cells.  Tissue infiltrating T-cells 
initiate local production of cytokines and growth factors.  The locally produced cytokines 
and growth factors may cause additional chemoattraction of fibroblasts, as well as, the 
transdifferentiation of tissue bound fibroblasts and smooth muscle cells in the vascular 
wall into myofibroblasts, cells with migratory abilities as well as increased capacity to 
produce collagen and other extracellular matrix components. Modulation of the function 
of tissue infiltrating T-cells at this stage could, thus, prevent or modify the vasculopathic 
process of systemic sclerosis. Some studies have suggested that statins could influence 
favorably these early events as indicated by investigations in the transplantation field 
showing that patients treated with statins were less likely to reject or to develop 
vasculopathy of the transplanted organ (23,24).  The mechanisms by which the statins 
can cause these effects are multiple.  For example, statins have been shown to down-
regulate the expression of numerous adhesion molecules on endothelial cells and 
lymphocytes, including monocyte chemotactic protein-1 (MAC-1 also known as M-2 
or CD11b/CD18) (25,26), intercellular adhesion molecule-1 (ICAM-1 or CD54) (27), and 
lymphocyte function associated antigen-1 (LFA-1 or CD11a/CD18 or L-2).  Statins 
also interfere with the interaction between ICAM-1 and LFA-1 by binding to the LFA-1 
L-site which is involved in the activation of lymphocytes by antigen presenting cells 
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(APC) (28, 29) (Figure 2). These effects inhibit the flux of lymphocytes into the sites of 
inflammation, which in turn leads to a decreased local production of cytokines and 
growth factors.  Furthermore, statins have been shown to inhibit the inducible expression 
of major histocompatibility complex class II (MHC II) in specialized antigen presenting 
cells (APC) such as dendritic cells, macrophages and B lymphocytes (30,31), thus, 
reducing antigen presentation to T-cells. 
 The pleiotropic effects of statins on immune cells including inhibition of 
lymphocyte activation by blocking antigen presentation, reduction of lymphocyte 
proliferation, and reduction of cytokine and growth factor expression suggest that these 
agents may exert novel therapeutic effects on immunologically mediated disorders. While 
it would be naïve to assume that the favorable results obtained in in vitro studies will 
correlate with similarly favorable effects in vivo, nonetheless clinical studies have 
focused on the potential use of statins in autoimmune mediated disorders, and early 
results in rheumatoid arthritis, antiphospholipid antibody syndrome, inflammatory 
arthritis, autoimmune encephalomyelitis and multiple sclerosis appear promising (32-35).  
 In relation to systemic sclerosis, an upregulation of MHC II complex, MCP-1 and 
ICAM-1 has already been described in fibroblasts and endothelial cells, especially early 
in the disease process.  These events appear to be necessary for the influx of fibroblasts 
and inflammatory cells into the vessel wall and the subsequent vessel wall fibrotic 
changes (36). The newly recognized effects of statins on the chemokines mentioned 
above may therefore inhibit the progression of the vasculopathy of systemic sclerosis and 
modify the disease.  Furthermore, interference with the ICAM-1-LFA-1 interaction may 
downregulate local inflammation and cytokine production. 
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 Statins as vasodilators.  A fundamental alteration in systemic sclerosis is the 
dysfunction or dysregulation of vascular tone in favor of a vasoconstricting response.  
The inherent damage to the endothelial cells which is believed to be one of the intial 
events in the pathogenesis of this vasculopathy leads to an increased ratio of endothelial 
derived vasoconstricting agents, such as endothelin and angiotensin II, as compared to 
endothelial derived vasodilating agents such as NO and prostacyclin. A similar imbalance 
has also been postulated between vasoconstricting and vasodilating neuromediators.  The 
predominant production of vasoconstricting molecules coupled with the exaggerated 
neurogenic vasoconstrictor response lead to further tissue ischemia and propagation of 
the disease process.  
The production of nitric oxide, the most important endothelium derived 
vasodilating agent, is downregulated in systemic sclerosis owing to endothelial 
dysfunction (Figure 2).  Besides its vasodilating effects, NO also inhibits platelet 
aggregation and adhesion, decreases endothelium permeability and local inflammatory 
cytokine production, and interferes with the adhesion of macrophages and leukocytes to 
the endothelium (37-40).  Thus, an increased production of NO would be expected to 
improve the vasculopathy of systemic sclerosis by  modifying favorably several 
pathogenic events.  Recent evidence has demonstrated that statins are capable of 
increasing NO production by causing an upregulation of endothelial derived nitric oxide 
synthase (eNOS); this effect is detectable as early as two weeks following the initiation of 
statin therapy and is mediated through two separate pathways.  One of these pathways is 
the stabilization of eNOS transcripts.  This effect appears to be mediated by inhibition of 
protein prenylation reactions by the statins.  Statins, as stated previously, do not only 
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inhibit cholesterol synthesis but also prevent farnesyl and geranylgeranyl prenylation of 
numerous molecules including members of the Rho and Ras-superfamilies of proteins 
(Figure 1).  The observation that the addition of geranyl geranyl pyrophosphate (GGPP) 
reverses in vitro the upregulation of eNOS expression induced by statins, whereas, 
addition of farnesyl pyrophosphate fails to reverse this effect suggests that geranylgeranyl 
synthesis and the geranylation of RhoA are directly related to the expression of eNOS.   
The second pathway by which statins appear to have an effect on eNOS is through the 
activation of the phosphatidylinositol (PI)-3-kinase/ protein kinase B(Akt) pathway since 
it has been shown that the serine-threonine protein kinase Akt phosphorylates and 
activates eNOS (41-44). 
Endothelin-1 (ET-1) is a potent endothelium derived vasoconstrictor protein 
which appears to play an important role in the pathogenesis of systemic sclerosis (Figure 
2).  The recent development of specific endothelin receptor blockers has shown that 
inhibition of ET-1 may be an effective therapy for the pulmonary arterial hypertension of 
systemic sclerosis.  This approach also appears promising for the peripheral vasculopathy 
and the interstitial lung involvement of this disorder (45).  Statins have two effects on the 
ET-1 pathway.  On the one hand, it has been shown that statins reduce pre-pro ET-1 
mRNA expression, an effect which appears to be mediated by the inhibition of 
geranylgeranyl prenylation of RhoA (46, 47).  A second mechanism appears to be the 
decrease in the expression of endothelin receptors in vascular cells (48). 
Recent work also has shown that both cerivastatin and fluvastatin downregulate 
endothelial angiotensin II type I receptors, an effect also mediated by inhibition of 
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prenylation of RhoA, thus potentially inhibiting the vasoconstrictive effect of angiotensin 
II (49).   
 Statins as antifibrotic agents.  Tissue fibrosis is the most prominent clinical 
manifestation of systemic sclerosis and is caused by the exaggerated accumulation of 
types I and III collagens and other connective tissue components in the extracellular 
matrix. Growth factors that play central roles in this process are transforming growth 
factor-1 (TGF-1) and connective tissue growth factor (CTGF) (3, 50) (Fig 2). Statins 
have been shown to downregulate the expression of TGF-1 by renal mesangial cells in 
models of renal nephropathy in which fibrosis is mediated by TGF-1 and CTGF (51, 
52).  Furthermore, statins cause potent reduction of CTGF mRNA levels in normal 
human and rodent mesangial cell lines, as well as, in human renal fibroblast cell lines, an 
effect also mediated by a decrease in geranylgeranyl prenylation of RhoA (53-55). 
 As part of the initiating events of any fibrotic disorder there is a proliferation or 
preferential selection of cells that have a profibrotic potential and/or transdifferentiation 
of cells with low extracellular matrix production capacity to cells with a much higher 
biosynthetic activity for molecules involved in the fibrotic process.  The mesangial cells 
play this central role in diabetic nephropathy and other fibrotic nephropathies, whereas, in 
hepatic fibrosis and pulmonary fibrosis, the responsible cells are the stellate cells and the 
lung myofibroblasts, respectively.  Statins have been shown in in vitro models of these 
fibrotic disorders to inhibit the proliferation of cells involved in the fibrotic process 
causing their increased apoptosis, as well as, causing a decrease in their production of 
extracellular matrix components.  These results suggest that statins may also have a 
beneficial effect in various fibroproliferative disorders (56-58).   
 Statins and systemic sclerosis vasculopathy 
11 
 Some studies have examined the effects of statins on cells from diseases 
associated with tissue fibrosis, however, only a few studied cells from patients with 
systemic sclerosis.  In a recent in vitro study employing systemic sclerosis skin 
fibroblasts, we showed that GGTI-296, a specific inhibitor of geranylgeranyl transferase 
1(GGT1) causes a potent inhibition (up to 80%) of the expression of genes encoding 
types I and III collagens (59).  This study suggested that inhibition of geranyl-geranyl 
prenylation by statins may also have similar effects to those of GGTI-296 on expression 
of collagen genes in systemic sclerosis fibroblasts.  We therefore examined the in vitro 
effects of lovastatin and simvastatin on collagen production and type I collagen mRNA 
levels in cultured normal and systemic sclerosis dermal fibroblasts.  We found that, 
indeed, both drugs were potent inhibitors of collagen production and caused a substantial 
reduction of collagen gene expression in these cells (60). In agreement with these results, 
another study showed that atorvastatin inhibited in a dose dependent manner ICAM-1 
expression on systemic sclerosis fibroblasts and reduced type I collagen production in 
both systemic sclerosis and normal fibroblasts (61).  
 Other statin effects.   Besides the immunomodulatory, vasodilating and 
antifibrotic effects discussed above, statins may also have antithrombotic and fibrinolytic 
effects by decreasing PAI-1 and increasing t-PA expression (62, 63) and may inhibit 
vascular smooth muscle cell proliferation (64), decrease the release of reactive oxygen 
species (65), inhibit platelet function (66) and increase prostacyclin production from both 
endothelial and vascular smooth muscle cells (67) (Figure 2).  These additional effects 
may also be of substantial value to improve the vasculopathy of systemic sclerosis. 
 
 Statins and systemic sclerosis vasculopathy 
12 
CONCLUSION 
 It has recently been recognized that statins display a remarkable array of 
important biological effects besides their well known cholesterol lowering effects.  It has 
also become recognized that most of these pleiotropic effects appear to be mediated 
through the inhibition of protein prenylation.  Protein prenylation results from the 
posttranslational covalent attachment of geranyl-geranyl or farnesyl groups into various 
proteins.  Protein prenylation causes crucial modifications of the function of target 
proteins including the activation of enzymatic or phosphorylation domains.  The Rho and 
Ras superfamilies of proteins are important targets for prenylation.  It has been 
hypothesized that these proteins modify the structure and function of cells in the vessel 
wall in manners that may prevent ischemic or proliferative vascular events.   However, it 
should be emphasized that not all statins possess this vast array of pleiotropic effects and 
that there are substantial differences among the statins in relation to the prenylation of 
Rho and Ras superfamilies of proteins in endothelial cells.  Extensive studies have shown 
that only hydrophobic statins have the ability to enter the endothelial cells and inhibit the 
mevalonate pathway.  
 The remarkable modulation by statins of such diverse pathogenic cascades such 
as those involved in immune mediated inflammatory reactions, vascular tone regulation, 
production of increased levels of NO, and regulation of collagen gene expression have 
provided a cogent rationale for the use of statins in disorders other than those related to 
hypercholesterolemic and atherosclerotic disease.  Indeed, some recent studies have 
examined the disease modifying effects of statins in disorders such as rheumatoid arthritis 
(34) and multiple sclerosis (35).  The vascular modifying effects discussed briefly here 
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provide strong support to the testable hypothesis that statins may be of benefit in the 
treatment of the vasculopathy of systemic sclerosis and suggest that it may prove 
rewarding to investigate these effects in pre-clinical and clinical studies for systemic 
sclerosis, a disease in which the prominent endothelial cell dysfunction and vascular 
abnormalities have been suggested to play a crucial role in its pathogenesis and evolution.   
 Thus, we posit here that in systemic sclerosis, a disease for which few proven 
disease modifying agents are available, statins, which are readily available and have been 
demonstrated to be remarkably safe, are a promising alternative which deserves further 
studies.  
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Figure 1.  Mevalonate pathway of cholesterol biosynthesis. 
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Key for Figure1: 
 
FPP-farnesyl pyrophosphate 
HMG CoA=hydroxyl-3-methylglutaryl Coenzyme A 
GGPP=geranylgeranyl pyrophosphate 
FTI=farnesyl transferase inhibitor 
GGTI=geranylgeranyl transferase inhibitor 
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Figure 2. Sites of potential action of statins on the pathogenesis of SSc 
vasculopathy.   
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Key for Figure 2: 
 
TGF-1: transforming growth factor beta 
CTGF: connective tissue growth factor 
PGI: prostacyclin 
ET-1: endothelin-1 
NO: nitric oxide 
LFA-1: lymphocyte function associated antigen-1 
ICAM-1: intercellular adhesion molecule-1 
MAC-1: monocyte chemotactic protein-1 
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